Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BQ.1.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DN.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CJ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBF.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.47NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.58NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.2.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.96NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EZ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.8.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GD.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBZNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BR.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.79NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FD.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.40NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.42NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.69NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.70NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used